1. Azevedo VF, Mysler E, Álvarez AA, Hughes J, Flores-Murrieta FJ, Ruiz de Castilla EM. Recommendations for the regulation of biosimilars and their implementation in Latin America. GaBI J. 2014;3(3):143–8. The expert panel’s perspectives on the current status led to six major recommendations in order to enhance the safe use of biosimilars in the Latin America region.
2. Bian J, Armitage JO, Ray P, Ablin RJ, Hruskesky WJ, Hermanson T, et al. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014;15(13):e594–605.
3. Regulation of similar biotherapeutic products in Latin America. Generics and Biosimilars Initiative. Published: Feb 8, 2013. http://gabionline.net/Biosimilars/Research/Regulation-of-similarbiotherapeutic-products-in-Latin-America Accessed November 2, 2015.
4. Araujo DV. Consideraciones Regulatorias sobre Productos Biológicos en Brasil. Value Health Reg Issues. 2012;1(2):254–6.
5. Argentinian guidelines for similar biological medicines. GaBI Online - Generics and Biosimilars Initiative. Global biosimilars guideline development – EGA’s perspective [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 May 3]. Available from: http://www.gabionline.net/Guidelines/Global-biosimilars-guideline-development-EGA-s-perspective Accessed November 2, 2015.